British drug maker AstraZeneca is considering acquiring cancer-drug developer Acerta Pharma, which operates in the Netherlands and California, The New York Times reports.
The news comes at a time when the pharmaceutical giant tries to grow its cancer treatment options.
It remains unclear if AstraZeneca will finalize such a deal or what the terms of a potential transaction would be.
Read the full story here.
More than 95 per cent of U.S. public pension funds employ at least one investment consultant, according to a new survey by Coalition Greenwich. The...
The Workplace Insurance and Safety Employees Trust generated a net return of 7.9 per cent in 2023, with net assets reaching $4 billion, up from...
A group of institutional investors is voicing concerns about the rise of virtual-only shareholder meetings they say risk eroding shareholder democracy. In an open letter...
Unifor has filed two applications with the B.C. Labour Relations Board to represent Amazon.com Inc. workers in New Westminster and Delta, B.C. “Workers at Amazon are seeking...
Generation Z and millennials say they’d expect a 10 per cent salary increase, on average, if they were unable to work in a hybrid working...
In anticipation of 25 per cent to 35 per cent growth in Canada by the end of 2024, restaurant chain Chipotle Mexican Grill Inc. is making...
Only a third (31 per cent) of U.K. pension plan members say they have sufficient retirement savings, down slightly from 32 per cent in 2022,...
Canadians’ happiness in the workplace increased to 6.8 points out of 10 in April, up slightly from 6.6 in March, according to a new survey by...